BMO Capital Remains a Hold on Gilead Sciences

By Ryan Adsit

BMO Capital analyst Ian Somaiya reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) on July 27 and set a price target of $82. The company’s shares closed yesterday at $75.94.

According to, Somaiya is a 5-star analyst with an average return of 13.0% and a 60.4% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Aeglea Biotherapeutics Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Gilead Sciences is Strong Buy and the average price target is $83.36, representing a 9.8% upside.

In a report issued on July 27, Maxim Group also reiterated a Hold rating on the stock.

Gilead Sciences’ market cap is currently $99.18B and has a P/E ratio of 8.25. The company has a book value ratio of 4.2951.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Gregg Alton, the EVP, Corp & Med Affairs of GILD sold 40,000 shares for a total of $2,960,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company’s products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.